LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

LLY

1,058.87

+1.65%↑

JNJ

203.92

+0.27%↑

ABBV

236.16

+2.85%↑

UNH

319.35

+2.41%↑

AZN

91.01

+2.64%↑

Начало・Списък с акции・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

546.92 1

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

546.14

Максимум

555.37

Ключови измерители
By Trading Economics
Приходи	-72M -114M
Продажби	74M 287M
EPS	-4.956
Марж на печалбата	-39.75
Служители	528
EBITDA	-75M -114M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+2.51% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	3.4B 13B
Предишно отваряне	545.92
Предишно затваряне	546.92

Настроения в новините

By Acuity

12%

88%

8 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

263.2 / 277.1 Подкрепа & съпротива

Madrigal Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.11.2025 г., 10:30 ч. UTC

Печалби

How Google Finally Leapfrogged Rivals With New Gemini Rollout -- WSJ

22.11.2025 г., 10:30 ч. UTC

Придобивния, сливания и поглъщания

Investors Clamor for a Peek Behind the Private Markets Curtain -- WSJ

22.11.2025 г., 09:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 22:42 ч. UTC

Пазарно говорене

Fitch Raises Cyprus's Outlook to Positive From Stable -- Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 21:47 ч. UTC

Пазарно говорене

Mexico's 3Q GDP Prompts Growth Downgrades -- Market Talk

21.11.2025 г., 21:43 ч. UTC

Пазарно говорене

U.S. Crude Production Defies Low Prices, Rig Count -- Market Talk

21.11.2025 г., 20:18 ч. UTC

Пазарно говорене

Oil Futures Fall on U.S. Push for Russia-Ukraine Peace -- Market Talk

21.11.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As Traders Focus on Weather -- Market Talk

21.11.2025 г., 19:48 ч. UTC

Пазарно говорене

Precious Metals Fall for the Week -- Market Talk

21.11.2025 г., 19:44 ч. UTC

Печалби

Deere Earnings, Inflation Data, Black Friday: What to Watch in the Next Week -- WSJ

21.11.2025 г., 19:37 ч. UTC

Пазарно говорене

Dollar Stalls as Stocks and Bonds Rise -- Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

21.11.2025 г., 19:27 ч. UTC

Пазарно говорене

Печалби

Intuit Seen With Underappreciated Credit Karma Momentum -- Market Talk

21.11.2025 г., 19:20 ч. UTC

Пазарно говорене

European Natural Gas Premium Versus U.S. Shrinks -- Market Talk

21.11.2025 г., 18:44 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Palo Alto-Chronosphere Synergies Questioned Despite M&A Record -- Market Talk

21.11.2025 г., 18:37 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises By 2 to 419 -- Market Talk

21.11.2025 г., 18:34 ч. UTC

Пазарно говорене

Печалби

Intuit Seen Outperforming on Conservative Guidance -- Market Talk

21.11.2025 г., 18:28 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 18:03 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Up Slightly in Early November -- Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.11.2025 г., 17:24 ч. UTC

Пазарно говорене

Intuit Seen on Path to Increase Growth -- Market Talk

21.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.11.2025 г., 17:05 ч. UTC

Пазарно говорене

Lowe's Getting Boost From Busy Small to Medium Pro Customer -- Market Talk

21.11.2025 г., 16:56 ч. UTC

Пазарно говорене

Gold Recovers as Investors Boost Rate-Cut Bets -- Market Talk

21.11.2025 г., 16:47 ч. UTC

Пазарно говорене

European Gas-Price Forecast to Decline Further on Expanding LNG Supply -- Market Talk

21.11.2025 г., 16:35 ч. UTC

Придобивния, сливания и поглъщания

What Stocks Al Gore's Investment Firm Bought and Sold This Quarter -- Barrons.com

21.11.2025 г., 16:09 ч. UTC

Печалби

Veeva Systems Earnings Beat Expectations. Why the Stock Is On Pace for Its Largest Drop Since 2023. -- Barrons.com

21.11.2025 г., 15:59 ч. UTC

Пазарно говорене

Canadian Consumers Tapping the Brakes, Still See Resilient -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Madrigal Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

2.51% нагоре

12-месечна прогноза

Среден 561.73 USD 2.51%

Висок 650 USD

Нисък 445 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Madrigal Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Madrigal Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

263.2 / 277.1Подкрепа & съпротива

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

8 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.